Bicycle and CRUK to launch first clinical trial of bicyclic peptide for use in treating tumours

Bicycle Therapeutics and Cancer Research UK have commenced the first clinical study to assess a bicyclic peptide to evaluate its potential in patients with advanced solid tumours. The first patient has now been dosed in a Phase I/IIa trial with BT1718, a first-in-class Bicycle Toxin Conjugate that targets Membrane Type 1 Matrix Metalloproteinase, which is

Continue Reading

Trial for Sandoz biosimilar hailed as ‘landmark’

Clinical data gathered for Sandoz’s biosimilar Etanercept (derived from Amgen and Pfizer’s Enbrel) was based from a “landmark” trial design in psoriasis in which over 500 patients switched from the original drug to the biosimilar. The data from the EGALITY trial showed the Novartis unit’s biosimilar, filed in the US and EU, met primary endpoint

Continue Reading